Peptide Showdown: BPC-157 vs TB-500
Our SARM Showdown series has become some of the most-read content on the Peak Body blog, so we're bringing the same head-to-head format to peptides. What better place to start than the two names that come up in every recovery discussion: BPC-157 and TB-500?
They are often mentioned together, and sometimes as if they were interchangeable. In fact they come from very different sources, are thought to work in different ways and have different kinds of research behind them.
All information is for educational and research purposes only.
BPC-157 — The Gut-Derived Healing Peptide
What it is: BPC-157 ("Body Protection Compound") is a 15-amino-acid peptide. Its sequence is taken from a protein found naturally in human gastric juice.
Research background: most BPC-157 research comes from one research group at the University of Zagreb, which has published a large number of animal studies since the 1990s. These studies have looked at healing in:
- tendon and ligament, including tendon-to-bone healing in rats
- muscle crush and tear injuries
- the gastrointestinal tract, including ulcers, fistulas and inflammatory bowel models.
Proposed mechanisms: research suggests BPC-157 may encourage new blood vessel growth (angiogenesis), interact with the nitric oxide system and increase growth hormone receptor levels in tendon cells (Chang et al., 2014). Its exact mechanism is still not fully understood.
Notable property: BPC-157 is unusually stable in gastric juice for a peptide. That's why it is one of the few peptides researched in oral forms as well as by injection. We covered this in our Peptide Tablets vs Capsules post.
Key research considerations: the animal research is extensive, but human data is very limited, consisting of only a few small pilot reports. Most of the literature also comes from a single research group, and independent replication would strengthen it. BPC-157 has been on the WADA Prohibited List (S0, non-approved substances) since 2022.
TB-500 — The Thymosin Beta-4 Peptide
What it is: TB-500 is a synthetic peptide based on thymosin beta-4 (Tβ4). Tβ4 is a naturally occurring protein found in almost every human cell and in especially high levels in blood platelets and white blood cells.
Research background: Tβ4's main natural job is controlling actin, the protein that forms the cell's internal scaffolding and lets cells move. That links it to processes that depend on cells moving to the right place, including:
- wound healing: Tβ4 has been shown to speed up skin wound repair in animal models (Malinda et al., 1999)
- heart tissue repair: a notable 2004 study in Nature (Bock-Marquette et al.) found Tβ4 helped heart muscle cells survive and migrate after injury in mice
- angiogenesis and inflammation control in a range of tissue models.
Human research: thymosin beta-4 itself has been studied in human clinical trials for conditions including dry eye and slow-healing wounds, with mixed results. There is little published research on the TB-500 fragment specifically.
Key research considerations: TB-500 and thymosin beta-4 are prohibited by WADA under S2 (peptide hormones, growth factors and related substances). As with BPC-157, most findings come from animal and cell models.
Side-by-Side Comparison
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Sequence from a gastric juice protein | Based on thymosin beta-4, found in most cells |
| Size | 15 amino acids | Synthetic Tβ4 peptide |
| Primary proposed mechanism | Angiogenesis, nitric oxide signalling, growth hormone receptor increase | Actin regulation, cell migration, angiogenesis |
| Main research focus | Tendon, ligament, muscle, gut | Wound healing, soft tissue, heart tissue |
| Tissue scope in research | Mainly local and targeted tissue models | Broader, whole-body tissue repair models |
| Stable in the gut? | Yes, unusually so | No |
| Human data | Very limited | Some for Tβ4; little for TB-500 specifically |
| WADA status | Prohibited (S0) | Prohibited (S2) |
Most researched for connective tissue: BPC-157. The tendon and ligament literature is where it stands out.
Most researched for broad tissue repair: TB-500. Its role in cell migration applies to many tissue types.
Most flexible for research formats: BPC-157, thanks to its stability in the gut.
Which Peptide Fits Which Research Goal
- Tendon, ligament and gut-focused research: BPC-157 has the most targeted literature.
- Wound healing, cell migration and cardiac models: TB-500 and thymosin beta-4 have the stronger research background.
- Comparing mechanisms: the two work in different ways, which is why they are so often discussed together. BPC-157 is linked to blood vessel growth and growth-factor signalling, and TB-500 to cell movement and structure.
The Verdict
BPC-157 and TB-500 are complementary rather than competing. BPC-157 is the targeted, gut-stable peptide with a deep base of animal research on connective tissue. TB-500 is the broader cell-migration peptide with its roots in thymosin beta-4 biology. Both share one big caveat: most of the evidence so far comes from animal studies.
Peptide quality depends heavily on correct handling. Before starting any research, see our How to Reconstitute Peptides guide. Independent lab reports for both BPC-157 and TB-500 are on our Independent Analysis page.
Further reading
- Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res.
- Chang CH et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules.
- Malinda KM et al. (1999). Thymosin β4 accelerates wound healing. J Invest Dermatol.
- Bock-Marquette I et al. (2004). Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature.
All products sold by Peak Body are strictly for research purposes only and are not intended for human consumption.
